A 78-Year-Old Man With Metastatic Melanoma and a 67-Year-Old Woman With Stage IV Melanoma : Episode 4
Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma
Hussein Tawbi, MD, PhD, explains that for patients with melanoma without a BRAF mutation, first-line therapies primarily include immunotherapy-based (IO) checkpoint inhibitors, with PD-1 inhibitor combination therapies being the current standard of care.
Recent Videos
Related Content
